Literature DB >> 11919736

Acute myeloid leukaemia of donor cell origin developing 5 years after allogeneic bone marrow transplantation for chronic myeloid leukaemia.

L Gopcsa1, A Barta, A Banyai, M Konya, L Pajor, J Földi, K Paloczi.   

Abstract

We report the case of a male patient with Ph-positive CML who developed AML 5 years after allogeneic BMT. Clinically, the AML seemed to develop on the basis of a myelodysplasia. The myeloid origin of blasts has been proven by immunophenotyping. The variable number of tandem repeats (VNTRs) and short tandem repeat (STR) showed donor-type haemopoiesis. The interphase FISH showed the XX genotype directly in the morphologically identifiable blasts and in the CD34-positive sorted bone marrow cells. This proved the new leukaemia to be of donor origin. The necessity of using multiple techniques and the advantage of combined immunophenotyping and FISH methods in this case is emphasized.

Entities:  

Mesh:

Year:  2002        PMID: 11919736     DOI: 10.1038/sj.bmt.1703378

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  9 in total

1.  First report of donor cell-derived acute leukemia as a complication of umbilical cord blood transplantation.

Authors:  Christopher J Fraser; Betsy A Hirsch; Vanessa Dayton; Michael H Creer; Joseph P Neglia; John E Wagner; K Scott Baker
Journal:  Blood       Date:  2005-08-23       Impact factor: 22.113

2.  Donor cell leukemia after umbilical cord blood transplantation: recurrent or de novo? The importance of diagnosis for therapeutic decision making.

Authors:  Yusuke Shono; Mizuha Kosugi-Kanaya; Souichi Shiratori; Junichi Sugita; Katsuya Fujimoto; Takeshi Kondo; Mitsufumi Nishio; Junji Tanaka; Masahiro Imamura
Journal:  Int J Hematol       Date:  2011-04-09       Impact factor: 2.490

3.  Myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: diagnostic and therapeutic challenges.

Authors:  Nirali N Shah; Ulrike Bacher; Terry Fry; Katherine R Calvo; Maryalice Stetler-Stevenson; Diane C Arthur; Roger Kurlander; Kristin Baird; Barbara Wise; Sergio Giralt; Michael Bishop; Nancy M Hardy; Alan S Wayne
Journal:  Am J Hematol       Date:  2012-04-04       Impact factor: 10.047

Review 4.  Donor cell-derived leukemia after cord blood transplantation and a review of the literature: differences between cord blood and BM as the transplant source.

Authors:  H Shiozaki; K Yoshinaga; T Kondo; Y Imai; M Shiseki; N Mori; M Teramura; T Motoji
Journal:  Bone Marrow Transplant       Date:  2013-09-09       Impact factor: 5.483

Review 5.  Genetics of donor cell leukemia in acute myelogenous leukemia and myelodysplastic syndrome.

Authors:  Lacey Williams; Kimberley Doucette; Judith E Karp; Catherine Lai
Journal:  Bone Marrow Transplant       Date:  2021-03-08       Impact factor: 5.483

Review 6.  Risks and mechanisms of oncological disease following stem cell transplantation.

Authors:  Sergey V Anisimov; Asuka Morizane; Ana S Correia
Journal:  Stem Cell Rev Rep       Date:  2010-09       Impact factor: 5.739

7.  Lessons Learned from Donor Cell-Derived Myeloid Neoplasms: Report of Three Cases and Review of the Literature.

Authors:  Komal Galani Deshmukh; Katalin Kelemen
Journal:  Life (Basel)       Date:  2022-04-08

8.  Salvage chemotherapy with donor lymphocyte infusion and STI 571 in a patient relapsing with B-lymphoblastic phase chronic myeloid leukemia after allogeneic bone marrow transplantation.

Authors:  László Gopcsa; Anikó Barta; Anikó Bányai; János Dolgos; Gabriella Halm; Katalin Pálóczi
Journal:  Pathol Oncol Res       Date:  2003-07-14       Impact factor: 3.201

9.  Acute myeloid leukaemia of donor cell origin developing 17 years after allogenic hematopoietic cell transplantation for acute promyelocytic leukaemia.

Authors:  Pilar Jiménez; J Carlos Alvarez; Pilar Garrido; J Antonio Lorente; Jorge Palacios; Francisco Ruiz-Cabello
Journal:  Int J Biomed Sci       Date:  2012-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.